Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 2 Withdrawn 1 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 438 Neoplasms 322 Carcinoma, Non-Small-Cell Lung 250 Prostatic Neoplasms 240 Lung Neoplasms 176 Colorectal Neoplasms 158 Pancreatic Neoplasms 148 Neoplasm Metastasis 142 Leukemia, Myeloid, Acute 140 Multiple Myeloma 131 Lymphoma 128 Carcinoma, Hepatocellular 127 Ovarian Neoplasms 109 Melanoma 109 Head and Neck Neoplasms 101 Brain Neoplasms 101 Recurrence 100 Leukemia 97 Leukemia, Lymphocytic, Chronic, B-Cell 96 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Glioblastoma 85 Lymphoma, Non-Hodgkin 83 Colonic Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 76 Lymphoma, Follicular 76 Carcinoma, Renal Cell 75 Lymphoma, Large B-Cell, Diffuse 71 Hematologic Neoplasms 69 Sarcoma 60 Stomach Neoplasms 58

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoid Heart Disease × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡